AML-193 Whole Cell Lysate: sc-364182

The AML-193 Whole Cell Lysate is derived from a human acute myeloid leukemia cell line, extensively used as a model to understand the molecular and cellular mechanisms of leukemia cells. Originating from the malignant hematopoietic cells of a patient, this lysate encompasses the entire repertoire of cellular components, including proteins, nucleic acids, and metabolites, characteristic of this leukemia subtype. Researchers employ the AML-193 lysate to explore the unique features of leukemia cells, such as their rapid proliferation rates, survival mechanisms, and the cellular pathways they utilize. This lysate has been particularly instrumental in non-clinical studies, serving as a critical resource for investigating gene expression profiles and identifying key regulatory proteins that are overexpressed or mutated in leukemia cells. By providing a detailed snapshot of the cellular constituents, the lysate facilitates various biochemical assays and molecular biology techniques, including Western blotting, ELISA, and mass spectrometry, which are essential for protein identification and quantification. Additionally, the AML-193 lysate is used in comparative studies with healthy blood cell lysates to uncover differences that could explain the pathogenesis of leukemia at the molecular level, aiding in a deeper understanding of cell behavior and interaction in a controlled environment.

AML-193 Whole Cell Lysate References:

1. Accumulated caveolae constitute subcellular compartments for glial calcium signaling in lanceolate sensory endings innervating rat vibrissae.  |  Takahashi-Iwanaga, H. and Iwanaga, T. 2012. J Comp Neurol. 520: 2053-66. PMID: 22173826